Assessing Neurodevelopmental outcomes of neonates with low blood sugars
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: E15-E16- Other disorders of glucose regulation and pancreatic internal secretion
- Registration Number
- CTRI/2022/03/041353
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
DetailsNeonates of gestation > 32 weeks with hypoglycemia (both symptomatic and asymptomatic) on hand held glucometer reading will be considered
Exclusion Criteria
1)Infants with major congenital malformations
2)Infants with persistent hypoglycemia secondary to panhypopituitarism or other endocrine causes
3)Infants with inborn errors of metabolism
4)Perinatal asphyxia
5)Parents who are unwilling to give consent for follow up visit at 6-9 months of life
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eurodevelopment outcomes in symptomatic (SH) vs asymptomatic (ASH) hypoglycemia using bailey scale of infant development & ages stages questionnaireTimepoint: At 6 months and 9 to 12 months corrected age
- Secondary Outcome Measures
Name Time Method (1)Mortality <br/ ><br>(2)aEEG abnormalities or changes <br/ ><br>(3)Presence of any seizure disorders <br/ ><br>(4)Vision outcomes <br/ ><br>(5)Hearing outcomes-BERA abnormalities and those on hearing aids <br/ ><br>(6)Tone abnormalities as defined by HINE score <br/ ><br>Timepoint: Total duration of NICU stay, at 6 months & 9-12 months corrected age